Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
    • Transcripts
    • AGM Invitations
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Nora AI
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team

You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?

BioPorto - Receives FDA clearance for NGAL test in the US

By HC Andersen Capital
BioPorto

Meet and ask questions to CEO Tony Paré from Bioporto on 11 December at 13:00 CET.

The focus will be on FDA 510(k) clearance for the NGAL test in the United States. This is the first test to aid in assessing AKI (Acute Kidney Injury) risk for patients aged 3 months through 21 years. The test will be marketed as ProNephro AKI™ (NGAL). Bioporto expects that US sales through its distribution agreement with Roche Diagnostics GmbH will begin in the second half of 2024.

Disclaimer: HC Andersen Capital receives payment from Bioporto for a DigitalIR/Corporate Visibility and IR advisory agreement./Claus Thestrup 13:05 8/12-2023.

Recent videos

Rapala H2'25: North American sales a highlight of the end of the year
12.03.2026 klo 17.25 Rapala VMC
Columbus – Presentation of Annual Report 2025
12.03.2026 klo 14.00 Columbus
Tokmanni Q4’25: Dollarstore’s turnaround is stalling
12.03.2026 klo 13.02 Tokmanni Group
Multitude, Webcast, Q4'25
12.03.2026 klo 11.00 Multitude
Rapala VMC Oyj, Audiocast, Q4'25
12.03.2026 klo 11.00 Rapala VMC
View all videos
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.